A cohort study has shown that metformin use reduces the risk of luminal A breast cancer (estrogen/progesterone receptor positive, human epidermal growth factor receptor 2 negative) in postmenopausal patients with type 2 diabetes (Chikermane et al., 2022). Here, ERBB2 is linked to breast cancer.